UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`FRESENIUS KABI USA, INC. and FRESENIUS KABI SWISSBIOSIM GmbH
`Petitioners,
`v.
`AMGEN, INC. and AMGEN MANUFACTURING LIMITED,
`Patent Owner.
`
`
`IPR2019-01183
`Patent No. 9,643,997
`Title: CAPTURE PURIFICATION PROCESSES FOR PROTEINS EXPRESSED
`IN A NON-MAMMALIAN SYSTEM
`
`
`DECLARATION OF PETER M. TESSIER, PH.D. IN SUPPORT OF
`FRESENIUS’S PETITION FOR INTER PARTES REVIEW
`OF U.S. PATENT NO. 9,643,997
`
`
`Mail Stop PATENT BOARD
`Patent Trial and Appeal Board
`United States Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`
`1 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`TABLE OF CONTENTS
`
`
`
`Page
`INTRODUCTION ............................................................................................... 6
` BACKGROUND AND QUALIFICATIONS ..................................................... 6
` BASES FOR OPINIONS AND MATERIALS CONSIDERED ........................ 9
` SUMMARY OF OPINIONS ............................................................................... 9
` LEGAL PRINCIPLES .......................................................................................11
`Burden of Proof ...................................................................................11
`
`Claim Construction..............................................................................12
`
`Prior Art ...............................................................................................12
`
` Anticipation .........................................................................................13
`Obviousness .........................................................................................15
`
`Person of Ordinary Skill in the Art .....................................................17
`
` TECHNICAL BACKGROUND: RECOVERY AND PURIFICATION OF
`RECOMBINANT PROTEINS ................................................................................17
`Protein Structure in General ................................................................17
`
`Protein Synthesis .................................................................................18
`
`Recovery and Purification of Bioactive Protein..................................19
`
`Step 1: Isolate and Purify the Inclusion Bodies .......................22
`
`Step 2: Solubilize the Inclusion Bodies ...................................22
`
`Step 3: Refold the Solubilized Protein .....................................24
`
`Step 4: Capture of Refolded Protein .........................................25
`
`Steps 5 and 6: Washing and Eluting .........................................28
`
` PERSON OF ORDINARY SKILL IN THE ART ........................................29
` U.S. PATENT 9,643,997 AND THE CHALLENGED CLAIMS ................30
`The Specification .................................................................................31
`
`The Challenged Claims .......................................................................35
`
`The File History of the ’997 Patent .....................................................38
`
`Claim Construction..............................................................................40
`
`“applying the refold solution to a separation matrix” ...............40
`
`
`2 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`“washing” and “eluting/elution” ...............................................43
`
`“isolate/isolated” .......................................................................44
`
`Expressly Defined Terms ....................................................................45
`
` SCOPE AND CONTENT OF THE PRIOR ART REFERENCES ..................48
` Wang (Ex. 1003) .................................................................................48
`Reardon (Ex. 1004) .............................................................................53
`
`Dietrich (Ex. 1005) ..............................................................................57
`
` Komath ’944 (Ex. 1006) ......................................................................59
`Komath ’056 (Ex. 1007) ......................................................................62
`
`Cutler (Ex. 1028) .................................................................................64
`
` DETAILED OPINIONS ....................................................................................65
` Ground 1: The Challenged Claims Are Anticipated by Wang ...........65
`Independent Claim 9 Is Anticipated by Wang (Ex. 1003) .......65
`
`The Preamble ..................................................................65
`
`Solubilization Step ..........................................................66
`
`Refold Step .....................................................................66
`
`Capture Step ....................................................................69
`
` Wash Step .......................................................................70
`Elution Step ....................................................................72
`
`Claims 10, 13-21, and 23-30 Are Anticipated by Wang ..........73
`
`Claim Chart ...............................................................................79
`
`Ground 2: The Challenged Claims Are Obvious over Wang in View
`
`of Cutler (Ex. 1028) .......................................................................................84
`Ground 3: The Challenged Claims Are Anticipated by Reardon .......85
`
`Independent Claim 9 Is Anticipated by Reardon ......................86
`
`The Preamble ..................................................................86
`
`Solubilization Step ..........................................................86
`
`Refold Step .....................................................................87
`
`Capture Step ....................................................................89
`
` Wash Step .......................................................................91
`Elution Step ....................................................................92
`
`
`3 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`Claims 10, 13-21, and 23-30 Are Anticipated by Reardon ......93
`
`Claim Chart ...............................................................................99
`
` Ground 4: The Challenged Claims Are Anticipated by Dietrich (Ex.
`1005) 102
`
`
`Independent Claim 9 Is Anticipated by Dietrich ....................103
`The Preamble ................................................................103
`
`Solubilization Step ........................................................103
`
`Refold Step ...................................................................104
`
`Capture Step ..................................................................105
`
` Wash Step .....................................................................107
`Elution Step ..................................................................107
`
`Dependent Claims 10, 13-21, and 23-30 Are Anticipated by
`
`Dietrich ..............................................................................................108
`Claim Chart .............................................................................113
`
`Ground 5: The Challenged Claims Are Obvious over Komath ’944 in
`
`Combination with Komath ’056 ..................................................................117
`Differences between the Prior Art and the Claimed Invention
`
`118
`The Challenged Claims Are Obvious over Komath ’944 and
`
`Komath ’056 ......................................................................................120
`Claim 9 Is Obvious over Komath ’944 in View of Komath ’056
`
`121
`The Preamble ................................................................121
`
`Solubilization Step ........................................................122
`
`Refold Step ...................................................................123
`
`Capture Step ..................................................................125
`
` Wash Step .....................................................................126
`Elution Step ..................................................................127
`
`Claims 10, 13-21, and 23-30 Are Obvious over Komath ’944 in
`
`View of Komath ’056 ........................................................................128
`No Secondary Considerations Support the Non-Obviousness of
`
`the Challenged Claims.......................................................................135
`
`
`
`
`
`4 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

` CONCLUSION ...............................................................................................136
`
`
`
`
`
`
`
`5 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`I, Peter M. Tessier, declare and state as follows:
`
`
`
`INTRODUCTION
`I have been retained on behalf of Petitioners in connection with their
`
`
`petition for inter partes review (“IPR”) of U.S. Patent No. 9,643,997 (“the ’997
`
`patent,” Ex. 1001). I am an expert in the field of protein engineering, including the
`
`commercial production of therapeutically useful proteins from non-mammalian
`
`cell cultures. Counsel for Petitioners have asked me to consider the patentability
`
`of claims 9-10, 13-21, and 23-30 of the ’997 patent (the “challenged claims”) in
`
`light of the prior art, and to provide a tutorial on the technology described in the
`
`’997 patent.
`
`
`
`The opinions set forth in this declaration are my own. I am being
`
`compensated at my usual rate of $600 per hour for the time spent preparing this
`
`declaration, and my compensation is not contingent on the outcome of this matter
`
`or on any of the opinions provided below.
`
` BACKGROUND AND QUALIFICATIONS
`I have performed research in the field of protein engineering for over
`
`
`fifteen years. My research regularly involves the purification of proteins expressed
`
`from mammalian and non-mammalian cell culture systems.
`
`
`
`I graduated from the University of Maine in 1998 as a Co-
`
`Valedictorian with a B.S. in Chemical Engineering. I subsequently earned a Ph.D.
`
`6 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`in 2003 from the University of Delaware in Chemical Engineering under the
`
`supervision of Professors Lenhoff and Sandler working on protein and nanoparticle
`
`interactions, solubility, crystallization, and self-assembly.
`
`
`
`I have worked in academia since the early 2000s. Following my
`
`Ph.D. studies, I worked as an American Cancer Society Postdoctoral Fellow at the
`
`Whitehead Institute for Biomedical Research (MIT) under the supervision of
`
`Professor Susan Lindquist, a specialist in molecular biology, and particularly
`
`protein folding, for which she received the National Medal of Science in 2010. In
`
`2007, I was appointed Assistant Professor at the Rensselaer Polytechnic Institute in
`
`the Department of Chemical & Biological Engineering at the Center for
`
`Biotechnology & Interdisciplinary Studies. From 2013 to 2016, I was promoted to
`
`Associate Professor and then the Richard Baruch M.D. Career Development
`
`(Endowed) Associate Professor, spending 2014 in Martinsried, Germany, at the
`
`Max Planck Institute for Biochemistry as an Alexander von Humboldt Fellow.
`
`
`
`In 2016, I was promoted to Full Professor at the Rensselaer
`
`Polytechnic Institute. In 2017, I became the Albert M. Mattocks (Endowed)
`
`Professor at the University of Michigan, Departments of Pharmaceutical Sciences,
`
`Chemical Engineering and Biomedical Engineering, a position I continue to hold
`
`today. I am also a member of the Biointerfaces Institute, a program designed to
`
`promote collaboration between life and physical scientists.
`
`7 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`
`
`Over the course of my career to date, I have received numerous
`
`awards for my research. Most recently I was awarded the National Science
`
`Foundation CAREER Award and the Alexander von Humboldt Fellowship for
`
`Experienced Researchers, and I was named a Fellow of the American Institute for
`
`Medical and Biological Engineering. I am a member of the American Chemical
`
`Society, the American Institute of Chemical Engineers and the Society of
`
`Biological Engineering.
`
` My current academic research focuses on the development of next
`
`generation technologies for designing, discovering, engineering, characterizing,
`
`formulating and delivering biologics ranging from small affinity peptides to large
`
`monoclonal antibodies for molecular imaging, diagnostic and therapeutic
`
`applications. My interdisciplinary research program aims to provide new
`
`fundamental insights related to protein structure and function, molecular origins of
`
`protein-protein interactions, and sequence and structural determinants of key
`
`protein properties, namely stability, solubility, specificity and affinity.
`
`
`
`Over the course of my career, I have worked on many projects
`
`investigating protein expression in both mammalian and bacterial host systems,
`
`protein refolding, and chromatographic purification technology. I have published
`
`60 peer-reviewed research and review papers, a book chapter on protein misfolding
`
`diseases, and am an inventor on one U.S. patent.
`
`8 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

` A list of my publications, abstracts presented at scientific conferences,
`
`appointments, affiliations, memberships in professional and research bodies and
`
`selected research projects are included in my curriculum vitae, attached as Exhibit
`
`1002A.
`
` BASES FOR OPINIONS AND MATERIALS CONSIDERED
` The opinions in this declaration are based on my review of the ’997
`
`patent, the applications and correspondence with the patent office that led to the
`
`’997 patent (which I understand is called the “file history”), the “prior art” and the
`
`other information cited in this declaration, as well as my extensive expertise as a
`
`protein engineer working with protein expression, folding, and purification
`
`processes. A list of the information I considered in preparing this declaration is
`
`attached at Ex. 1002B.
`
` SUMMARY OF OPINIONS
` The challenged claims (9–10, 13–21, and 23–30), are directed to the
`
`purification of any protein expressed in a non-mammalian system in a limited
`
`solubility form (such as inclusion bodies) by (a) solubilizing the protein in a
`
`solution containing reagents that cause the proteins to disaggregate and unfold, (b)
`
`forming a refold solution by diluting the solubilization solution into a buffer
`
`containing reagents that allow the protein to properly refold, (c) applying the refold
`
`solution to any “separation matrix” under conditions suitable for the protein to
`
`9 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`associate with the matrix, (d) washing the matrix, and (e) eluting the protein. As
`
`exemplified in the references I discuss below, scientists routinely used this
`
`sequence of steps to purify proteins expressed in non-mammalian cells as of June
`
`25, 2009, the earliest possible priority date of the ’997 patent.
`
`
`
`I understand that Patent Owner (“PO”) has asserted that the claimed
`
`process improved upon the prior art by eliminating the need to remove components
`
`of the refold solution before applying the protein to the separation matrix.
`
`However, as I discuss further below, scientists before 2009 had already purified
`
`proteins expressed in a non-mammalian system without intervening steps to
`
`remove components of the refold solution, and they understood that such
`
`intervening steps were not necessary for the purification of all proteins using all
`
`separation matrices.
`
` After reviewing the prior art and applying the legal standards (set
`
`forth below) provided by counsel, I have concluded that the challenged claims are
`
`not patentable. In summary, the protein purification techniques described in the
`
`’997 patent had been described and taught in the prior art before the earliest filing
`
`date of the ’997 patent.
`
` Each element of the protein purification process described in claims
`
`9–10, 13–21, and 23–30 is disclosed in Wang (Ex. 1003), Reardon (Ex. 1004), and
`
`10 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`Dietrich (Ex. 1005). These claims are not patentable because each of Wang,
`
`Reardon, and Dietrich “anticipates” them.
`
` Moreover, all of the challenged claims would have been obvious from
`
`the combined disclosures of Komath ’944 (Ex. 1006) and Komath ’056 (Ex. 1007);
`
`or the combined disclosure of Wang (Ex. 1003) and Cutler (Ex. 1028).
`
` From these references, and from the general knowledge in the field,
`
`any “person of ordinary skill in the art” would have known how to purify proteins
`
`expressed in a non-native limited solubility form in a non-mammalian expression
`
`system, by using the routine steps recited in the challenged claims. The claims
`
`therefore are not patentable.
`
` LEGAL PRINCIPLES
` To assist me in performing my assessment of patentability, counsel
`
`for Petitioners have informed me about the legal standards for patentability set
`
`forth below.
`
` Burden of Proof
`I understand that in order to be eligible for a patent, an invention must
`
`
`(among other requirements) be both new and not obvious from the prior art to a
`
`person of ordinary skill in the relevant technical field. In an IPR, a claim is not
`
`patentable if a “preponderance of the evidence” establishes that the claim is
`
`11 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`anticipated by, or would have been obvious from, the prior art. I understand “a
`
`preponderance of the evidence” means “more likely than not.”
`
` Claim Construction
`I understand that in an IPR, the terms in a patent claim are generally
`
`
`given their ordinary and customary meaning as understood by a person of skill in
`
`the art in the context of the entire patent disclosure and the file history (together,
`
`the “intrinsic” evidence).
`
`
`
`If, however, a patentee provides a specific definition for a claim term
`
`in the patent disclosure, then the patentee’s definition applies. If the patentee
`
`chooses to provide a definition, however, it must be done with reasonable clarity,
`
`deliberateness and precision.
`
`
`
`I understand that some claims are “independent” and do not refer to,
`
`or incorporate, any portion of any other claim. I also understand some claims are
`
`“dependent” and refer to other claims by number. The dependent claims include
`
`all of the limitations of the claims to which they refer (i.e. “depend” from). A
`
`“multiple dependent” claim is any dependent claim which refers to more than one
`
`other claim and refers to such other claims in the alternative only.
`
`
`
`
`
`Prior Art
`I have been instructed to assume for purposes of my analysis that June
`
`25, 2009, is the relevant date for determining what is “prior art.” In other words, I
`
`12 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`should consider as “prior art” any reference that was published prior to June 25,
`
`2009.
`
`
`
`I further understand that a reference is a “printed publication” if it was
`
`disseminated or otherwise made available such that persons of ordinary skill in the
`
`art, exercising reasonable diligence, could locate it.
`
` Anticipation
`I understand that a patent claim is anticipated if a single prior art
`
`
`document discloses every element of the claim to a person of ordinary skill in the
`
`art.
`
`
`
`I understand that in order to anticipate, a prior art reference must
`
`generally disclose all elements of the claim arranged as in the claim. However, if
`
`the reference does not expressly spell out all the limitations arranged or combined
`
`as in the claim, it can still anticipate if a person of skill in the art, reading the
`
`reference, would at once envisage the claimed arrangement or combination.
`
`
`
`I understand that even if the prior art reference does not expressly
`
`disclose a particular claim element, the prior art may still anticipate if that element
`
`is “inherent” in the disclosure. A claim element is inherent if it is necessarily
`
`present in, or is the natural result of, subject matter disclosed in a prior art
`
`reference.
`
`13 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

` Regarding process claims, I understand that if a prior art process does
`
`not expressly disclose a step of a claimed process but necessarily results in the
`
`performance of that step, then the step is inherent in the prior art process. In
`
`addition, I understand that a prior art device may be relied upon for anticipation of
`
`a method claim if the method claim is directed to a function which the prior art
`
`device “in its normal and usual operation,” will perform.
`
`
`
`I understand that an inherent element must necessarily be present in or
`
`result from what is disclosed in a prior art reference, and that inherency may not be
`
`established by probabilities or possibilities.
`
`
`
`I also understand that while anticipation must be based on a single
`
`prior art reference, additional references can be used to make clear that a missing
`
`claim element is necessarily present in the subject matter described in the
`
`reference. References that are not prior art can be used to demonstrate inherency.
`
`
`
`I understand that a prior art publication must be “enabling” in order to
`
`anticipate a patent claim. Prior art is enabling if it describes the claimed method
`
`sufficiently to allow a person of ordinary skill in the art to carry out that method.
`
`
`
`I understand that a claim written in “multiple dependent form” is
`
`invalid if any dependency of the claim can be shown to be invalid. For example, I
`
`understand that a multiple dependent claim depending from any of claims A, B,
`
`and C is invalid if the claim covers invalid subject matter when construed to
`
`14 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`depend from claim A, even if the claim does not cover invalid subject matter when
`
`construed to depend from claim B or claim C.
`
` Obviousness
`I understand that a patent claim is obvious if the differences between
`
`
`
`the claim and the prior art are such that the subject matter as a whole would have
`
`been obvious to a person of ordinary skill at the time the claimed invention was
`
`made. For purposes of my analysis, I have been asked to assume a prior art cutoff
`
`date of June 25, 2009.
`
`
`
`I understand that when assessing whether a claim is obvious, I should
`
`consider: (i) the scope and content of the prior art; (ii) the level of ordinary skill in
`
`the art; (iii) the differences between what is claimed and the prior art; and (iv) any
`
`secondary considerations that may indicate whether the claim is obvious or not.
`
`
`
`I understand that a claimed invention may be obvious when, for
`
`example, there is some teaching, suggestion or motivation in the prior art that
`
`would have led a person of ordinary skill in the art to modify the prior art reference
`
`or to combine prior art teachings to arrive at the claimed invention, with a
`
`reasonable expectation of success.
`
`
`
`I also understand that a claim can be found obvious if, based on the
`
`prior art, it would have been obvious for a person of ordinary skill in the art to try
`
`15 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`the claimed invention by choosing from a finite number of identified, predictable
`
`solutions, with a reasonable expectation of success.
`
`
`
`I understand that “secondary” evidence may weigh against a finding
`
`that a claimed invention would have been obvious. This secondary evidence
`
`includes: (i) commercial success of a product due to the merits of what is provided
`
`in the patent claim; (ii) a long-felt but unsolved need for the solution provided by
`
`the patent claim; (iii) unsuccessful attempts by others to find the solution provided
`
`by the patent claim; (iv) copying by others of what is claimed in the patent; (v)
`
`unexpected results that arise from what is provided in the patent claim; (vi)
`
`industry skepticism regarding what is provided in the patent claim; (vii) praise
`
`from others in the field; and (viii) simultaneous invention by others.
`
`
`
`I understand that in order to be probative of non-obviousness,
`
`secondary evidence must have a “nexus” to the merits of the claimed invention. In
`
`other words, the evidence must be related to the claimed invention and not what
`
`was known in the prior art. For example, I understand that where alleged
`
`commercial success actually results from something other than what is both
`
`claimed and novel in the claim, then there is no nexus to the merits of the claimed
`
`invention.
`
`16 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`
`
`
`
`Person of Ordinary Skill in the Art
`I have been informed by counsel that a patentability analysis is to be
`
`conducted from the perspective of a person of ordinary skill in the art to which the
`
`claimed invention pertains at the time it was made. I understand that a person of
`
`ordinary skill in the art is a hypothetical person that is presumed to have perfect
`
`knowledge of all of the relevant prior art, and is often referred to as a “person of
`
`ordinary skill in the art” or “POSA.”
`
`
`
`I have been informed by counsel that in defining a POSA, the
`
`following factors may be considered: (1) the educational level of the named
`
`inventor; (2) the type of problems encountered in the art; (3) prior art solutions to
`
`those problems; (4) rapidity with which innovations are made; and (5)
`
`sophistication of the technology and educational level of active workers in the
`
`field.
`
` TECHNICAL BACKGROUND: RECOVERY AND PURIFICATION
`OF RECOMBINANT PROTEINS
` To assist the reader in understanding my opinions regarding the prior
`
`art and claims, I have prepared a tutorial on the relevant scientific techniques and
`
`principles.
`
`Protein Structure in General
`
` Proteins are complex molecules made up of chemical subunits known
`
`as “amino acids” that are joined together by “peptide bonds” into long chains, like
`
`17 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`beads on a string. ’997 patent at 6:8–11 (“the terms ‘protein’ and ‘polypeptide’ are
`
`used interchangeably and mean any chain of at least five naturally or non-naturally
`
`occurring amino acids linked by peptide bonds”). Proteins can perform their
`
`biological function only if this “polypeptide” chain is folded into a precise three-
`
`dimensional shape. Creighton 1999 (Ex. 1008) at 2020. The correct, functional
`
`three-dimensional shape of a protein is often called the “native” form or structure.
`
`Protein Synthesis
`
` Proteins are naturally produced in both mammalian cells (e.g., mouse
`
`and human cells) and non-mammalian cells (e.g., yeasts and bacteria, such as
`
`Escherichia coli (commonly known as “E. coli”)). These organisms create
`
`proteins by “transcribing” or duplicating information encoded in DNA to generate
`
`an RNA molecule with the same encoded sequence, which then serves as a
`
`template for the synthesis of a protein. Whitford (Ex. 1009) at 247; see also,
`
`Horton (Ex. 1010) at 683–711. The genetic information stored in RNA is
`
`“translated” or read by the ribosomes of the cell, which then use the information to
`
`make protein molecules with the correct amino acid sequence. Id. This process of
`
`transcription (from DNA to RNA) and translation (from RNA to a protein) is
`
`known as “biosynthesis.”
`
` Proteins can also be synthesized in the lab using recombinant DNA
`
`technology, which has been known in the art since at least the late 1970s. Ex. 1010
`
`18 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`at 719. A recombinant DNA molecule is constructed with DNA from different
`
`sources, for example by inserting a segment of DNA that codes for a protein of
`
`interest into another segment that facilitates insertion into the genes of a host cell.
`
`Id.
`
` When recombinant DNA is inserted into a cell, it enables the cell to
`
`produce the protein of interest. Id. at 734-35 In essence, recombinant DNA
`
`technology turns a host cell into a “factory” to create large amounts of the desired
`
`protein in an efficient manner. Id. These host cells replicate into colonies that
`
`produce the desired proteins on a larger scale. Proteins that are synthesized
`
`(commonly called protein “expression”) using recombinant DNA technology are
`
`called “recombinant” proteins. Id.
`
` While recombinant proteins can be expressed in several different host
`
`systems, E. coli expression systems have been among the most widely used for
`
`large-scale production of proteins because they are relatively easy to use, quick,
`
`and inexpensive. Id. at 734–35.
`
` Recovery and Purification of Bioactive Protein
` Following expression, recombinant proteins must be folded into their
`
`precise native three-dimensional shape to function properly. Unfolded or mis-
`
`folded proteins lack function and are particularly prone to aggregation, typically
`
`because “hydrophobic” residues (amino acids that have lower solubility in water)
`
`19 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`that are normally buried within the interior of the properly-folded protein are
`
`exposed on their surfaces. Hydrophobic residues tend to stick to other
`
`hydrophobic residues, which causes mis-folded protein strands to clump together
`
`and form particles of aggregated protein. Stirling 2003 (Ex. 1011).
`
` While bacterial host cells, such as E. coli, have the advantage of
`
`efficiently synthesizing proteins, they often have difficulty producing properly
`
`refolded recombinant proteins, in particular, proteins that are normally not
`
`produced by the bacteria. When expressing recombinant proteins, bacteria often
`
`express misfolded proteins that clump together in the cell within what are known
`
`as “inclusion bodies,” as shown in the image below of a bacteria cell expressing
`
`protein:
`
`
`(Modified from Profacgen (Ex. 1012)). Inclusion bodies are “insoluble,
`
`biologically inactive aggregates of partially folded protein.” Ex. 1008 at 1250.
`
`20 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`
`
`In order to recover therapeutically useful, biologically active proteins
`
`from these inclusion bodies, they must be “solubilized” to allow the proteins to
`
`disaggregate and unfold, and then the proteins must be “refolded” into their native
`
`three-dimensional shapes (these concepts are explained more fully below). Id. at
`
`1251. The proteins must also be purified from components of their solubilization
`
`and refolding solutions as well as remaining cell debris.
`
` Techniques for recovering and purifying native, folded proteins in a
`
`bioactive and stable form from inclusion bodies were well known by 2009. As
`
`early as 1998, there were “over 300 reports of mammalian, plant, and microbial
`
`proteins obtained and renatured from inclusion bodies formed in E. coli.”
`
`Georgiou (Ex. 1014) at 48.
`
` These techniques generally began with recovery of refolded proteins
`
`by (1) isolating and purifying the inclusion bodies; (2) solubilizing the inclusion
`
`bodies, resulting in unfolding of proteins; and (3) refolding of the solubilized
`
`protein. See generally Clark 1998 (Ex. 1015) at 47–54.
`
` The solution obtained after refolding usually contained undesired
`
`impurities along with properly refolded proteins. Therefore, it was typical to
`
`purify the refolded proteins using one or more conventional chromatography
`
`methods. Following step (3), these conventional purification methods typically
`
`involved (4) applying the protein solution onto a chromatography matrix under
`
`21 of 137
`
`Fresenius Kabi
`Exhibit 1003
`
`

`

`conditions in which the protein will temporarily adhere to or “associate with” the
`
`matrix; (5) “washing” the column using one or more solutions to remove
`
`contaminants from the adhered proteins; and (6) removing or “eluting” the protein
`
`from the matrix by applying one or more solutions that cause the protein to
`
`dissociate from the matrix. See, e.g., Dietrich (Ex. 1005) at [008], [0072]; Cutler
`
`(Ex. 1028) at 128-129. The now purified proteins are then eventually isolated from
`
`the eluate. I discuss each of these steps in additional detail below.
`
`Step 1: Isolate and Purify the Inclusion Bodies
`
` To obtain protein synthesized from, for example, bacterial host cells,
`
`the host cells were lysed, the contents of the cell were released, and the resulting
`
`suspension was centrifuged to separate the lighter soluble portion (containing non-
`
`target soluble proteins) from the heavier insoluble portion (containing the inclusion
`
`bodies and cellular debris). Ex. 1009 at 318-22; see also Clark 2001 (Ex. 1016) at
`
`202–06, Bollag 1996 (Ex. 1017) at 44–46. The inclusion bodies were then isolated
`
`from the cellular debris in the insoluble fraction and washed to remove
`
`contaminants.
`
`Step 2: Solubilize the Inclusion